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ABSTRACT
Skin toxicity (ST) is a frequent adverse effect (AE) in anti-epidermal growth 
factor receptor (EGFR)-targeted treatment of metastatic colorectal cancer (mCRC) 
resulting in decreased quality of life and problems in clinical management. We 
wanted to identify biomarkers predicting ST in this setting and focused on 70 DNA 
polymorphisms associated with acne, the (immunoglobulin fragment crystallizable 
region) Fcγ-receptor pathway, and systemic lupus erythematosus (SLE) applying 
next-generation-sequencing (NGS). For the analysis patients with mCRC treated 
with cetuximab were selected from the FIRE-3 study. A training group consisting 
of the phenotypes low (1) - and high-grade (3) ST (n = 16) and a validation group  
(n = 55) representing also the intermediate grade (2) were genotyped and investigated 
in a genotype-phenotype association analysis. The single nucleotide polymorphism 
(SNP) rs849142 significantly associated with ST in both the training- (p < 0.01) 
and validation-group (p = 0.04). rs849142 is located in an intron of the juxtaposed 
with another zinc finger protein 1 (JAZF1) gene. Haplotype analysis demonstrated 
significant linkage disequilibrium of rs849142 with JAZF1. Thus, rs849142 might be 
a predictive biomarker for ST in anti-EGFR treated mCRC patients. Its value in the 
clinical management of AE has to be validated in larger cohorts.
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INTRODUCTION
Skin toxicities (ST) like papulopustular rash 
(acneiform eruption), erythema, skin fissures, hair and 
nail changes, paronychia, and xerosis are frequent adverse 
effects (AE) when targeting the EGFR in solid cancers 
like metastatic colorectal cancer (mCRC), lung cancer, 
head and neck cancers and others [1]. ST occurs mostly 
at the face, scalp and trunk within the first three weeks or 
during the second cycle of treatment with variable severity 
in 82% of mCRC-patients receiving targeted anti-EGFR-
treatment [2–5]. 38–70% of the patients also demonstrated 
bacterial but seldom viral infections at sites of ST [2, 6] 
all of which negatively affected quality of live [2, 7–9]. 
ST is treated pre-emptively and symptomatically applying 
special creams as well as oral and topical treatment [7, 
10]. It is unknown if these compounds interfere with anti-
EGFR targeted therapy. The severity of ST is classified 
by a simple three tier grading system -Common Toxicity 
Criteria for Adverse Events (CTCAE)-: grade 1 (mild; 
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~40% of the patients), grade 2 (moderate, ~40%), and 
grade 3 (severe, ~20%) (National Cancer Institute; 
CTCAE. http://evs.nci.nih.gov/) [3]. Interestingly, ST is 
an on-treatment marker for the efficacy of the anti-EGFR 
targeted therapy [2, 5, 8, 9, 11]. Despite its acneiform 
appearance, it differs both etiologically and pathologically 
from acne as for example comedones are missing [7]. 
Reasons for ST might be alterations in the cytokine/ 
chemokine profile, disturbed keratinocyte differentiation, 
barrier defects due to xerosis or infection [2]. Predictive 
biomarkers for ST were investigated and include a 
polymorphism in intron 1 of the EGFR-gene influencing 
expression levels [9, 12], expression of inflammatory 
lymphokines [13], and serum levels of EGFR-ligands 
[14–16]. Unfortunately, the predictive value of these 
biomarkers is either low or was not validated. Thus, 
none of these biomarkers found its way into clinical 
practice. Therefore, we searched for biomarkers which are 
predictive for ST in mCRC and identified the rs849142 
SNP as a potentially predictive biomarker for ST in anti-
EGFR treated mCRC patient cohort of the FIRE-3 study.
RESULTS
Skin toxicity is significantly associated with 
survival in a FIRE-3 study collective
As only a limited number of specific biomarkers 
predicting ST is available which has not been approved 
for clinical use [16] our aim was to identify and validate 
potentially clinically useful predictive biomarkers for ST. 
Therefore, we chose a sub-collection of mCRC patients 
from the FOLFIRI plus cetuximab arm of the FIRE-3 
study [17, 18]. A training/ validation approach was chosen 
including 16 randomly selected mCRC patients with 
ST grade 1 or 3 for the training group (mean age 64.2 
years) and 55 patients in the validation group (mean age 
62.4 years) with ST grade 1, 2, and 3 (Table 1). To see if 
this subpopulation of the FIRE-3 study still represented 
the complete group of patients we tested for the known 
correlation of the ST-grade induced by anti-EGFR therapy 
with the survival of the patients [9] employing Kaplan–
Meier statistics. In the chosen subgroup ST grade and 
survival statistically correlated with both progression 
free survival (PFS; p < 0.001) and overall survival (OS; 
p < 0.001) comparably to the whole patient collective 
(Figure 1). Similar results were also obtained when the 
training- and validation sets were tested independently 
(PFS, p-training set = 0.016, p-validation set = 0.004; 
OS, p-training set = 0.059, p-validation set < 0.004) 
(Supplementary Figure 1).
Thus, representative subgroups of patients of the 
clinical FIRE-3 study were available which were therefore 
enrolled as the data-basis for subsequent steps in the 
identification of predictive biomarkers for anti-EGFR 
therapy induced ST.
SNPs known to be associated with acne, FcRγ, 
and SLE were selected for the investigation of ST 
in mCRC patients treated with cetuximab
Because ST is most likely a tumor-independent 
AE mediated by anti-EGFR antibody treatment, we 
hypothesized that single nucleotide polymorphisms (SNP) 
which are known to be related to other ST like acne [19–
21], systemic lupus erythematodes (SLE) [22], or FcRγ-
signaling [23, 24] might also be indicative for anti-EGFR 
treatment related ST. Appropriate markers were selected 
from the literature [6, 19–24] and public databases (https://
www.snpedia.com) (Figure 2). All together 14 SNP 
associated with acne, 20 SNPs with FcRγ, and 36 with SLE 
were identified as potential markers for ST (Figure 2). Six 
of these SNPs were found in both the SLE- as well as the 
FcRγ-subgroup. Thus, together 64 SNPs were employed 
in an NGS-approach for the investigation of ST in mCRC 
patients treated with anti-EGFR antibodies. After multiple 
steps of NGS quality control testing (Supplementary 
Figure 2) a set of 61 SNPs and 71 patients remained for 
the linkage analysis of SNPs associated with ST. 
SNP rs849142 is significantly associated with ST 
related to cetuximab
To investigate a possible association between 
genotypes (SNPs) and severity of ST the genetic linkage 
analysis routine of the PLINK software [25] was applied 
for both the training- and validation set (Figure 3). It turned 
out that rs849142 (T allele) was significantly associated 
with ST in both the training- (p = 0.004, Sens = 100.00%, 
Spec = 83.33%, PPV = 80.00%, NPV = 100.00%, Figure 
3A) and validation group (p = 0.0436, Sens = 86.36%, 
Spec = 44.44%, PPV = 79.17%, NPV = 57.14%, Figure 
3B) as well as in the whole patient collective (p = 0.004, 
Supplementary Figure 3). In contrast rs849142 (T allele) 
only correlated significantly with PFS in the training 
group (p = 0.05) (Supplementary Figure 4) but neither 
with OS in the training- nor PFS and OS in the validation 
group. rs849142 did not deviate significantly from Hardy-
Weinberg equilibrium (p = 0.44, Supplementary Table 2). 
Also another SNP, rs463426, significantly correlated 
with ST in the validation- (p = 0.036) and whole group 
(p < 0.001), but showed only a trend for statistical 
significance in the training group (p = 0.066). Therefore, 
rs463426 was excluded from further analyses.
Global allele frequencies of rs849142 (T; C) are 
given as T: 0.765, C: 0.235, T|T: 0.615, C|C: 0.086, C|T: 
0.299 (1000 Genomes Project) showing strong variations 
in different ethnicities (for details refer to Figure 4A). 
The European population displays almost balanced 
allele frequencies (T: 0.492, C: 0.508) compared to the 
East Asian population (T: 0.985, C: 0.015). Our results 
(Table 2) are expectedly in line with this data-set for the 
European subpopulation (T: 0.419, C: 0.581) which is 
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another indicator for the support for the correctness of our 
measurements (Figure 4A). It turned out that the T-allele 
especially in the homozygous form (T|T) indicates high 
grade ST (Table 2).
rs849142 is located in the JAZF1 gene
In a next step, we wanted to know if the genomic 
localization of rs849142 might help to elucidate a possible 
molecular mechanism. Therefore, database searches and 
in silico analyses were performed. rs849142 is located on 
chromosome 7 within an intronic region of the Juxtaposed 
with Another Zinc Finger protein 1 (JAZF1) gene (Figure 
4B). JAZF1 is a transcriptional regulator that directly 
represses transcription or acts as a corepressor [26]. JAZF1 
was not shown to be directly associated with ST but one 
of its interaction partners, Transforming growth factor 
β-activated kinase 1 (TAK1) is an integral component of 
signaling pathways involved in modulating the immune 
response [27]. The intronic position of rs849142 does not 
allow to conclude on a potential influence on transcriptional 
regulation of the JAZF1 gene. Unfortunately, no skin 
samples from our patient collective or other ST studies 
were available to measure the JAZF1 mRNA expression 
profile. It is known that JAZF1 is ubiquitously expressed 
with highest levels in the adrenal gland and whole blood 
and lowest expression in the ST/ immune response-
associated organs skin, spleen, and thyroid (expression 
data from: gtexportal.org (2)) (Figure 4C). Additionally, 
the expression of JAZF1 correlates inversely with the 
levels of the cetuximab target EGFR in the skin and whole 
blood (Figure 4C). Taken together, these results suggest 
that JAZF1 itself may not be directly involved in the 
development of cetuximab-mediated ST.
To explore a potential bystander effect indicated by 
linkage of rs849142 with other genes a linkage analysis 
of SNPs neighboring rs849142 was performed (Figure 
5). rs849142 was only found in a coupling group with the 
SNPs rs864745 and rs849140 which are both located in 
the JAZF1 gene. Therefore, rs849142 is also in linkage 
disequilibrium (LD) with several other SNPs within 
JAZF1 and the adjacent non-protein coding JAZF1-AS1 
(antisense RNA 1) gene (Figure 4B). But also JAZF1-AS1 
has not been associated with ST, thus the connection of the 
SNP rs849142 and ST remains unknown like mutations 
in the FOXL2 gene in granulosa cell tumors of the ovary 
[28]. Definitely, more research has to be invested.
DISCUSSION
In our study collective, the SNP rs849142 (T allele) 
was identified and validated as a potential biomarker 
for skin-related adverse effects in mCRC patients under 
targeted anti-EGFR treatment using cetuximab (FIRE-3 
study). Thus, genotyping of the rs849142 might help to 
improve decision-making on prophylactic ST treatment in 
Table 1: Composition of the evaluated training and validation patient groups
Group Age Sex Skin toxicity
mean male female unknown 1 2 3
Training (n = 16) 64.2 6 (37.50%) 7 (43.75%) 3 (18.75%) 11 (68.75%) 0 (0.00%) 5 (31.25%)
Validation (n = 55) 62.4 43 (78.18%) 12 (21.82%) 0 (0.00%) 19 (34.55%) 16 (29.09%) 20 (36.36%)
Figure 1: PFS and OS Kaplan–Meier plots for cetuximab associated ST grades.
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the situation of targeted anti-EGFR treatment of left-sided 
and wildtypic (WT) KRAS- and NRAS gene mCRCs. 
In such a scenario, the high-risk group of patients with 
a T|T constellation of rs849142 might be considered 
for prophylactic ST treatment. As rs849142 is a genetic 
marker its testing has several advantages: First, higher 
sensitivity and specificity than measurements of variable 
day-to-day parameters like mRNA or serum components 
[13] and serum-level markers (AREG, EREG, HGF). 
Second, SNP detection can be measured easily from liquid 
biopsies (blood, saliva) and is less invasive than taking 
tissue biopsies. Third, SNP-typing can be performed 
together with the testing for mutations in the KRAS- und 
NRAS-genes as the predictive test for using anti-EGFR 
targeting antibodies in the therapy of mCRC. Due to the 
different global distribution of rs849142 alleles in distinct 
Figure 2: SNPs and respective genes selected for targeted sequencing (complete results in Supplementary Table 1). 
FcRγ, Fc receptor γ; SLE, systemic lupus erythematodes. SNP; single nucleotide polymorphism.
Table 2: Distribution of rs841942 in the patient collective
Training ST Grade 1 ST Grade 2 ST Grade 3 Sum
No variant call 5 (83.33%) 0 (0%) 1 (16.67%) 6
C/C 5 (100%) 0 (0%) 0 (0%) 5
C/T 1 (20%) 0 (0%) 4 (80%) 5
T/T 0 (0%) 0 (0%) 0 (0%) 0 
Sum 11 0 5 16
Validation ST Grade 1 ST Grade 2 ST Grade 3 Sum
No variant call 1 (33.33%) 0 (0%) 2 (66.67%) 3
C/C 8 (57.14%) 3 (21.43%) 3 (21.43%) 14
C/T 8 (27.59%) 11 (37.93%) 10 (34.48%) 29
T/T 2 (22.22%) 2 (22.22%) 5 (55.56%) 9
Sum 19 16 20 55
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Figure 3: Manhattan plot for ST of patients from the Training group (A) or Validation group (B). SNP position on the chromosome 
is indicated by horizontal position. Y-axis value describes magnitude of evidence for association calculated as -log10(p value). Chr., 
chromosome.
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ethnicities SNP-testing might be especially valuable 
for Europeans (T: 49.2%, C: 50.8%) and Americans (T: 
65%, C: 35%) but less for Africans (T: 84.9%, C:15.1%) 
and especially East Asians (T: 98.5%, C:1.5%). Due to 
the small size of our collections, the missing correlation 
with survival as well as underling molecular mechanism, 
these results are preliminary. Further research especially 
validation in larger cohorts is essential.
For our aim to find biomarkers predicting ST in anti-
EGFR treatment of mCRC patients, we chose a training/ 
validation approach in a patient collective of the FIRE-3 
study [17, 18]. Our kind of approach includes a high bias 
as the statistic variance is high due to the low amounts of 
events. For this reason seldom events might be missed. The 
alternative is a linkage analysis which requires numbers 
of events in the range of several hundreds to thousands. 
It is questionable if such high numbers of patients with 
documented ST grade are accessible even globally. Another 
major drawback of small collections might be a drift in 
the representativity compared to the whole collection. 
Therefore, we confirmed by applying an additional ST 
unrelated parameter, namely the response to anti-EGFR 
directed therapy [9], that our sub-selection still reflected 
the whole FIRE-3 patient cohort. Another bias in training/ 
validation approaches is the need for an input of pre-
selected parameters; in our case the collection of SNPs under 
investigation. Therefore, three non-oncological diseases 
were chosen, because ST in mCRC patients is most likely 
a tumor independent effect. 1: Acne is a common disease 
linked to deregulation and changes in the skin environment 
[29]. 2: SLE is an autoimmune disease that commonly 
results in skin-related manifestations [30]. 3: Imunoglobulin 
fragment crystallizable receptors (FcR) are responsible for 
unspecific binding of antibody-classes via the Fc-region 
of the antibody which might result in the joining of tumor- 
with other (immune) cells eventually resulting in antibody-
dependent cell-mediated cytotoxicity (ADCC) or other kinds 
of interference. SNPs are known to influence the affinity of 
FcRs for immunoglobulins [31]. As cetuximab is an IgG1 
antibody the class of FcRγ was of interest for our study. This 
approach resulted in a total of 61 SNPs which are known 
to modulate acne, SLE, and FcRγ binding. Of these only 
rs849142—found in the SLE group—was significantly 
associated with ST in both the training and validation group.
Figure 4: (A) Global- and sub-population allele frequencies of rs849142 (T>C) in comparison to the FIRE-3 patient collective as 
annotated at 1000genomes.org. (B) JAZF1 genomic region on Chromosome 7. JAZF1 and adjacent genes are shown. Position of rs849142 
is indicated by the blue line. Reading direction of JAZF1 indicated by an arrowhead. Vertical bars indicate exons. JAZF1, Juxtaposed with 
another zinc finger protein 1. JAZF1-AS1, JAZF1 antisense RNA 1. (C) mRNA expression of JAZF1 (upper panel) and EGFR (lower 
panel) in various and ST related tissues as obtained from http://www.gtexportal.org. Expression is presented in RPKM (reads per kilobase 
of transcript per million mapped reads).
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As ST correlates with survival of mCRC patients 
[9], it was reasonable to check if this was also true for 
rs849142. Unexpectedly, a significant association of 
rs849142 (T allele) was only observed for PFS in the 
training group. No correlation was present with OS in 
the training set nor PFS and OS in the validation group. 
Thus, ST and response or survival seem to share several 
but differ in other characteristics. Underlying molecular 
mechanisms are unknown and thus arguing would be 
speculative. Moreover, as rs849142 is located in the 
intron of JAZF1 aside from functional relevant sites like 
splice donor/acceptor it is idle to discuss a possible role 
or function. For sure both open questions need further 
research.
Taken together, our study revealed rs849142 as 
a potentially predictive biomarker of ST in cetuximab 
treated mCRC patients. Patients may largely benefit 
from a prediction of ST and potentially the severity of 
the disease by genotyping rs849142 as physicians could 
manage ST in the relevant population of patients thereby 
treating only that subset of patients where ST will occur 
as an AE of the anti-EGFR targeted treatment. Moreover, 
reading out the genotype of the rs849142 alleles can easily 
be incorporated into the detection pipeline for the analysis 
of other relevant molecular biomarkers for mCRC, namely 
mutations in the BRAF-, KRAS- and NRAS-genes as well 
as microsatellite instability [32]. Finally, it is important to 
note that our finding has to be validated in a larger cohort 
or at best in the setting of a prospective clinical study.
MATERIALS AND METHODS
Patients
The FIRE-3 study was a randomized phase 3 study 
of stage IV mCRC patients (age 18–75 years) treated 
with the combinatorial-chemotherapy (CTX) folinic 
acid, leucovorin, 5-Fluoruracil (5-FU), and Irinotecan 
(FOLFIRI) with either cetuximab or bevacizumab. The 
inclusion criteria for FIRE-3 study have been described 
in detail before [17]. Further inclusion criteria for this 
particular analysis were: Appropriate follow-up data, 
cetuximab treatment group presence of remaining DNA 
samples. ST grades were determined using the common 
Figure 5: Linkage Disequilibrium (LD) Plot of Chromosome 7 28150kB ± 100 kB using Version 2 release 24 CEU 
(CEPH, Utah residents with ancestry from northern and western Europe). SNPs are presented in their genomic order. 
rs849142 is indicated by blue arrow. The reading direction (arrowhead) and exons (vertical bars) of the JAZF1 and the partially overlapping 
JAZF1-AS1 genes are indicated on top. The degree of positive correlation between two SNPs is visualized by color-coded squares at 
the intersection of orthogonal lines originating from each variant: White: low LD, low confidence; Shades of pink/red: low LD, high 
confidence; blue: high LD, low confidence; bright red: high LD, high confidence.
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toxicity criteria of adverse events (CTCAE) version 4.0. 
For a training-validation approach, two subgroups of the 
cetuximab treatment arm were analyzed: 1) training group 
(n = 16) consisting of patients with grade one and three 
ST; 2) validation group (n = 55) including patients with 
ST grade one, two, and three. For this approach, from all 
eligible patients showing ST grade 1 or 3, sixteen were 
assigned randomly to the training group. All other eligible 
patients were included into the validation group before the 
analysis.
DNA extraction and genotyping
Genomic DNA was isolated from peripheral blood 
mononuclear cells using QIAGEN blood kits following 
the vendor’s recommendations and used as the template 
for a targeted next-generation-sequencing (NGS) approach 
together with custom sequencing panels. Therefore, three 
Ion Ampliseq™ Custom DNA-Hotspot panels were 
designed utilizing Ion Torrent Ampliseq® Custom Panel 
Designer (Supplementary Table 1). They were used 
together with Ampliseq™ Library kits for preparing 
libraries which were analyzed on an NGS IonTorrent 
PGM™ (Personal Genome Machine, Thermo Fisher 
Scientific) platform. The experimental procedures were 
done according to the manufacturer’s manual. Briefly, 
DNA concentration and quality was measured using 
the Qubit™ 3 Fluorimeter (Thermo Fisher Scientific). 
The concentration of amplifiable DNA was quantified 
using an RNase P-gene specific detection system (Roche 
Diagnostics). Samples with a ratio of >2 were extracted 
again. Amplicon libraries were created using the Ion 
Ampliseq™ Library Kit 2.0 (Thermo Fisher Scientific) 
with 21 PCR cycles. For comparable coverage of the 
samples, DNA concentration was controlled for by the 
Ion Torrent qPCR quantification following the vendor’s 
instructions. Groups of 16 libraries were transferred into 
the IonChef™ pipetting station for clonal amplification by 
emulsion PCR and Ion-316™ Chip loading. Chips were 
loaded onto the IonTorrent PGM™ (Personal Genome 
Machine, Thermo Fisher Scientific).
Statistical analysis
Analysis of data obtained by NGS was done applying 
the Ion Reporter™ v.4.6 software: data quality was 
controlled for by application of filter criteria recommended 
by the vendor. Reads were mapped to the reference genome 
hg19 and variants were called using the standard settings. 
SNP annotation was based on dbSNP138. Resulting 
variant calling files (VCF) were reformatted to match 
specifications of the PLINK software version 1.07 [25]. Of 
note, SNPs showing more than two alleles were excluded 
from the analysis, because they cannot be evaluated in a 
typical quantitative genetic association analysis. Overview 
tables on quality based on patients and variants were 
calculated using the summary statistics function of the 
PLINK software. The fraction of successfully genotyped 
variants was visualized in Haploview version 4.2 
(Supplementary Figures 3 and 4) [33]. The exact Hardy-
Weinberg equilibrium (HWE) test module of PLINK 
was used for calculating deviations from HWE applying 
a significance level of p < 0.001. Genotype-phenotype-
association was estimated for each group using the Wald 
statistic in PLINK measuring ST as a quantitative marker. 
Results were visualized as Manhattan plots (Haploview 
software). Sensitivity [Sens], specificity [Spec], positive 
predictive value [PPV] and negative predictive value [NPV] 
were calculated comparing the genotype corresponding 
to ST grade 1 and to all other genotypes and ST grades. 
Linkage disequilibrium analysis of a region spanning 
100 kb upstream and downstream of rs849142 was run 
with the Haploview software and haplotype blocks were 
calculated [34]. Pooled over strata p-values of survival 
analyses were calculated with the SPSS 23.0 software 
using log-rank- and Kaplan–Meier models.
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